KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Nektar Therapeutics (NKTR) over the last 15 years, with Q3 2025 value amounting to $18.9 million.

  • Nektar Therapeutics' Shares Outstanding (Weighted Average) rose 3581.91% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year increase of 3581.91%. This contributed to the annual value of $205.7 million for FY2024, which is 824.21% up from last year.
  • Nektar Therapeutics' Shares Outstanding (Weighted Average) amounted to $18.9 million in Q3 2025, which was up 3581.91% from $14.1 million recorded in Q2 2025.
  • Nektar Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $210.9 million during Q1 2025, with a 5-year trough of $13.9 million in Q2 2024.
  • In the last 5 years, Nektar Therapeutics' Shares Outstanding (Weighted Average) had a median value of $186.8 million in 2022 and averaged $153.2 million.
  • Per our database at Business Quant, Nektar Therapeutics' Shares Outstanding (Weighted Average) plummeted by 9267.36% in 2024 and then surged by 3581.91% in 2025.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Shares Outstanding (Weighted Average) stood at $183.3 million in 2021, then rose by 2.09% to $187.1 million in 2022, then rose by 1.53% to $190.0 million in 2023, then rose by 8.24% to $205.7 million in 2024, then plummeted by 90.79% to $18.9 million in 2025.
  • Its last three reported values are $18.9 million in Q3 2025, $14.1 million for Q2 2025, and $210.9 million during Q1 2025.